Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Promatix Biosciences Wins Innovate UK Grant for Cancer ADC Program | Contract Pharma

What are you searching for?

Sign in
Breaking News

Promatix Biosciences Wins Innovate UK Grant for Cancer ADC Program

Funding will support preclinical development of PBS293-exatecan for colorectal cancer and other solid tumors.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Promatix Biosciences Ltd, a UK-based biotechnology company developing innovative new classes of cancer therapies, has been awarded a grant under the Innovate UK Biomedical Catalyst 2025: Industry-led R&D small projects competition, which will support continued development of the company’s lead program, PBS293-exatecan, an EGFR × EphA2 cis-bispecific ADC for the treatment of CRC and other solid tumors.

The award will fund the scale-up and conjugation of PBS293 with an exatecan payload, additional preclinical proof-of-concept studies in both CDX and PDX models of CRC, and IND-enabling regulatory safety studies to support the nomination of PBS293-exatecan as a development candidate. In parallel, Promatix will apply its discovery platform to evaluate oesophageal cancer and NSCLC as additional indications. The work will be conducted with established UK-based contract research organizations, including Abzena, Crown Bioscience and Labcorp UK.

“This award from Innovate UK enables us to generate the additional preclinical data needed to move PBS293-exatecan towards development candidate nomination,” said Dr. Roy Pettipher, Chief Scientific Officer and Co-Founder of Promatix. “By scaling up our lead conjugate and testing it in both cell-line and patient-derived models, alongside the regulatory safety studies expected for an ADC, we plan to assemble the industry-standard data package that partners and investors are looking for.”

“Non-dilutive funding of this kind is strong external validation of both our lead program and the proteomics-driven discovery platform behind it,” added Dr. Michael Hunter, CEO and Co-Founder of Promatix. “It will enable us to advance PBS293-exatecan in colorectal cancer while extending the same logic-gated approach to further solid  tumors, including oesophageal and non-small cell lung cancer.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics